Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

QN 247

Next Previous
Search
Drug Profile

QN 247

Alternative Names: ALAN (AS1411-GNP); ALAN-RE; Aptamer linked anti nucleolin - Qualigen Therapeutics; AS 1411 GNP; AS1411-GNPs; GNP AS1411; QN-247; QN-247RE

Latest Information Update: 07 May 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Louisville
  • Developer Qualigen Therapeutics; University of Louisville
  • Class Antineoplastics; Drug conjugates; Nucleotide aptamers; Oligonucleotides
  • Mechanism of Action Nucleolin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Acute myeloid leukaemia; Neuroblastoma; Pancreatic cancer; Triple negative breast cancer

Most Recent Events

  • 08 Apr 2024 Discontinued - Preclinical for Acute myeloid leukaemia in USA (Parenteral) as of April 2024
  • 08 Apr 2024 Discontinued - Preclinical for Neuroblastoma in USA (Parenteral) as of April 2024
  • 08 Apr 2024 Discontinued - Preclinical for Pancreatic cancer in USA (Parenteral) as of April 2024

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top